Zusammenfassung
Durch die Arzneimittelgesetzgebung des Jahres 2003 sind Medikamente, die den Kriterien
der evidenz-basierten Medizin nicht entsprechen, nicht mehr verfügbar. Einschränkungen
der Indikation haben die medikamentösen Behandlungsmöglichkeiten der Narkolepsie
zusätzlich stark reduziert. Zur Beseitigung der Unsicherheit, die bei der
Verordnung nicht mehr indizierter Präparate bestehen, wird ein Überblick über
die im In- und Ausland erhältlichen Medikamente zur Behandlung von Tagesschläfrigkeit
und Kataplexien gegeben.
Summary
Due to pharmaceutical legislation some drugs that did not meet the criteria of
evidence based medicine were taken from the market in 2003. Restriction of indication
caused further reduction fo narcolepsy medication. This caused some confusion
in the medical community concerning prescription. To resolve the uncertainties
this article gives an overview of the presently available drugs for treatment
of excessive daytime sleepiness and cataplexies.
Literatur
- 1
Challman T D, Lipsky J J.
Methylphenidate: its pharmacology and uses.
Mayo Clin Proc.
2000;
75
711-721
- 2
Cook H. for the US Xyrem Multicenter Study Group .
A randomized, double blind, placebo-controlled multicenter trial comparing the
effects of three doses of orallly administered sodium oxybate with placebo for
the treatment of narcolepsy.
Sleep.
2002;
25
42-49
- 3
Daniels E, King M A, Smith I E, Shneerson J M.
Health-related quality of life in narcolepsy.
J Sleep Res.
2001;
10
75-81
- 4
Engber T M, Koury E J, Dennis S A, Miller M S, Contreras P C, Bhat R V.
Differential patterns of regional c-Fos induction in the rat brain by amphetamine
and the novel wakefulness-promoting agent modafinil.
Neuroscience Letter.
1998;
241
95-98
- 5
Ferraro L, Tanganelli S, O}Connor W T. et al .
The vigilance promoting drug modafinil decreases GABA release in the medial
proptic area and in the posterior hypothalamus of the awake rat: possible involvement
of the serotonergic 5-HT3 receptor.
Neurosci Lett.
1996;
220
5-8
- 6
Guilleminault C, Mancuso J, Quera-Salva M A. et al .
Viloxacine hydrochloride in narcolepsy: A preliminary report.
Sleep.
1986;
9
275-279
- 7
Larrosa O, da la Llave Y, Bario S. et al .
Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy:
a pilot study.
Sleep.
2001;
24
282-285
- 8 Mayer G. Narkolepsie. 1. Ausgabe, 187 Seiten Blackwell Wissenschafts-Verlag,
Berlin, Wien 2000
- 9
Mitler M, Harsh J, Hirshkowitz M. et al .
Long-term efficacy and safety of modafinil for the treatment of excessive daytime
sleepiness associated with narcolepsy.
Sleep Med.
2000;
14
53-60
- 10
Scammell T E.
The neurobiology, diagnosis and treatment of narcolepsy.
Ann Neurol.
2003;
53
154-166
- 11
Silber M H, Krahn L E, Olson E J, Pankratz V S.
The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based
study.
Sleep.
2002;
2
197-204
- 12
Standards of Practice Committee .
Practice Parameters for the treatment of narcolepsy: An update for 2000.
Sleep.
2001;
24
45-56
- 13
US Modafinil in Narcolepsy Multicenter Study Group .
Randomized trial of modafinil as a treatment for the excessive daytime somnolence
of narcolepsy.
Neurology.
2000;
54
1166-1175
- 14
Tanganellli S, Fuxe K, Ferraro L. et al .
Inhibitory effects of the psychoactive drug modafinil on gamma-aminobutyric
acid outflow from the cerebral cortex of the awake freely moving giunea-pig.
Possible involvement of 5-hydroxytryptamine mechanisms.
Haunyn Schmiedebergs Arch Pharmacol.
1992;
345
461-465
Prof. Dr. med. Geert Mayer
Hephata Klinik
Schimmelpfengstraße 2
34613 Schwalmstadt-Treysa
Phone: 06691/182002
Fax: 06691/182040
Email: geert.mayer@hephata.com
